(Date:1/8/2009)...ONTO, Jan. 8 /PRNewswire-FirstCall/ - Med-Emerg In... Canada,s leading providers of health services, is...ted in favour of the previously announced plan of ...oup Inc. ("AIM") at a special meeting of MedEmerg,... 90% of the votes cast at the meeting were in favo...
(Date:1/8/2009)...XANDRIA, Va., Jan. 8 To...nization along with several national leadership or... the principles of hospice care and protection of ...anding together in sharing this unified message ab...of Hospice and Palliative Medicine, Hospice and Pa...
(Date:1/8/2009)...ifornia Assembly Member Tom Torlakson Introduces A...-USNewswire/ -- Today, Lung Cancer Alliance-Cali... Tom Torlakson (D-11th District) for his continued...unding for lung cancer research. For the third co...ancer research is being considered in the Californ...
(Date:1/8/2009)...says it lowered bad cholesterol more effectively t...y News) -- After nearly a year of review, U.S. hea...e continued use of the controversial cholesterol-l...Administration said there was no significant diffe... taking Vytorin and patients taking the drug Zocor...
Breaking Medicine News(10 mins):Health News:Shareholders of Med-Emerg International Inc. approve plan of arrangement with AIM Health Group Inc. 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:FDA Backs Cholesterol Drug Vytorin 2... walk and stick to healthy food. That is a far mor... a group of US scientists has said.// In fact pr...tified when lifestyle changes are just as effectiv...osiglitazone pills do work, but so does weight los...
...ch has shown a way for people suffering diabetic r...arding as well as alleviating the effects of diabe... consequence of diabetes. In the initial stages, ...le symptoms but is capable of progressing graduall...
... outcomes for blacks with cardiovascular disease a...ferences in access and treatment are minimized, ac...rt Journal, Reuters reports. For the study, Nanc...emorial Veterans Hospital and colleagues studied t...
...w of the massacre that took place last week at the...iversity officials are asking the congressmen to f...isaster. Some kind of program, to identify and tre... and the others. A law that would permit the unive...
Other Medicine News:Health News:Lifestyle changes not prescription drugs to fight diabetes, say scientists 2Health News:Measures Needed to Avert Another Bloodbath 2...3, 2007 - Affymax, Inc.,(Nasdaq:AFFY) today announ...ical trials of Hematide(TM) in dialysis and,non-di...data showed,that in treatment naive, non-dialysis ...stered monthly at an appropriate dose.,Similarly, ...ith,three-times weekly Epoetin Alfa demonstrated t...
...7 - CytRx Corporation,(NASDAQ:CYTR) today announce...logy exclusively licensed to its majority-owned,su...as been,published in the April 2007 issue of peer-...The technology was developed by RXi,Co-founder, Sc...assachusetts Medical School (UMMS) Professor of Bi...
Other Medicine Technology:Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 2Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4Angled shafts with 4 mm tying patform. Serrated handle with dull finish. Most popular size or model. Overall length 3.2 inches.
Angled 45 degree shafts 8 mm from tip to bend with 4 mm tying platform. Smooth handle with dull finish. Overall length 3.2 inches.
Curved shafts and tips with 6 mm tying platform. Wide serrated handle with dull finish. Overall length 4.3 inches.
Ultra-fine tying platform with round knurled handle for fingertip rotational control. Straight shafts. Overall length 3.9 inches.
Medicine Products: